We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 01, 2017

Abemaciclib Effective as a Single Agent in Refractory HR+/HER2− Metastatic Breast Cancer

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
MONARCH 1, a Phase 2 Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients With Refractory HR+/HER2- Metastatic Breast Cancer
Clin. Cancer Res 2017 May 22;[EPub Ahead of Print], MN Dickler, S Tolaney, HS Rugo, J Cortés, V Dieras, DA Patt, H Wildiers, CA Hudis, JA O'Shaughnessy, E Zamora, D Yardley, M Frenzel, AG Koustenis, J Baselga

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading